SEARCH

SEARCH BY CITATION

References

  • 1
    Rodriguez-Bano J, Alcala JC, Cisneros JM et al. Community infections caused by extended spectrum beta lactamase producing Escherichia coli. Arch Intern Med 2008; 168: 18971902.
  • 2
    Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2008; 29: 671674.
  • 3
    Coque TM, Novais A, Carattoli A et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta-lactamase CTX-M-15. Emerg Infect Dis 2008; 14: 195200.
  • 4
    Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V et al. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 61: 273281.
  • 5
    Yumuk Z, Afacan G, Nicolas-Chanoine MH et al. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008; 62: 284288.
  • 6
    Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum beta lactamase producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 10891094.
  • 7
    Sobel JD, Kaye D. Urinary tract infections. In: MandellGL, BennettJE, DolinR, eds. Principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone, 2005; 875905.
  • 8
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; Eeighteenth informational supplement. CLSI Document M100-S18. Wayne, PA: CLSI, 2008.
  • 9
    Saladin M, Cao V, Lambert T et al. Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. FEMS Microbiol Lett 2002; 209: 161168.
  • 10
    Arslan H, Azap ÖK, Ergönül Ö, Timurkaynak F. Risk factors for ciprofloxacin resistance among E. coli strains isolated from community acquired urinary tract infections in Turkey. J Antimicrob Chemother 2005; 56: 914918.
  • 11
    Calbo E, Romani V, Xercavins M et al. Risk factors for community onset urinary tract infections due to Escherichia coli harbouring extended spectrum beta lactamases. J Antimicrob Chemother 2006; 57: 780783.
  • 12
    Colodner R, Rock W, Chazan B et al. Risk factors for the development of extended-spectrum beta-lactamase producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004; 23: 163167.
  • 13
    Yılmaz E, Akalın H, Özbey S et al. Risk factors in community acquired/onset urinary tract infections due to extended-spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae. J Chemother 2008; 20: 581585.
  • 14
    Canbaz S, Peksen Y, Sunter AT et al. Antibiotic prescribing and urinary tract infection. Int J Antimicrob Agents 2002; 20: 407411.
  • 15
    Knottnerus BJ, Nys S, Ter Riet G et al. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in the Netherlands? J Antimicrob Chemother 2008; 62: 356359.
  • 16
    Ena J, Francisco A, Martinez-Peinado C et al. Epidemiology of urinary tract infections caused by extended spectrum beta lactamase producing Escherichia coli. Urology 2006; 68: 11691174.
  • 17
    Lagace-Wiens PRS, Nichol KA, Nicolle LE et al. Treatment of lower urinary tract infection caused by multi-drug resistant extended-spectrum beta lactamase producing E. coli with amoxicillin/clavulonate: case report and characterization of the isolate. J Antimicrob Chemother 2006; 57: 12621263.
  • 18
    Aktaş Z, Gönüllü N, Schneider I et al. Detection of CTX-M-15 type extended spectrum beta-lactamase in an Escherichia coli strain isolated from the urine sample of a hospitalized patient. Mikrobiyol Bul 2005; 39: 421429.
  • 19
    Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community acquired infections. Ann Intern Med 2002; 137: 791797.